We write checks anywhere from $5M – $75M. We often lead, but can also invest as part of a syndicate. We are thesis driven and seek founders that are attacking systemic problems in large end markets. While we are generalists, a lot of our activity tends to be in Healthtech, Fintech and DeepTech.
Multi-strategy, singular focus
Venture and Growth Equity
We partner with companies from Series A and beyond
Life Sciences
Backing passionate, driven teams with deep domain knowledge
We have a successful history of investing in drug delivery technologies as well as preclinical and early clinical-stage assets within CNS, inflammation/immunology, oncology and biosimilars. We offer our partners access to our industry expertise, broad network of relationships, and active support in building their businesses over multi-year time horizons. Today, we maintain a portfolio of control and minority investments that span all stages from start-up to mature and publicly-traded.
Real Estate
We have completed $1B+ in hotel acquisitions and development
Honed over decades of hands-on experience, our fundamental approach to real estate has not changed: creatively identify hidden value and execute with speed and certainty. From single assets to portfolios, leases, debt, branded or independent, limited service or luxury, we are opportunity agnostic and focused on maximizing
ROI.
Tarsadia Capital
New York-based investment management vehicle of Tarsadia
Tarsadia Capital has a flexible and long-duration investment mandate that focuses on public and private equities and commodities globally. Our investment process employs deep fundamental research on secular inflections to identify and build conviction around asymmetric risk/reward opportunities that will play out over multi-year time horizons.